Please login to the form below

Not currently logged in
Email:
Password:

Medivation

This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.

Latest news

More from news
Approximately 15 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.

  • Deal Watch August 2016 Deal Watch August 2016

    So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.

  • Deal Watch May 2016 Deal Watch May 2016

    on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC

  • Deal Watch April 2016 Deal Watch April 2016

    Sanofi would like to merge with Medivation as it makes “ strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics